Renalytix AI is listed on the London Stock Exchange so there’s...

Renalytix AI is listed on the London Stock Exchange so there’s plenty of information available if you want to see it (LON: RENX). Market cap of GBP191m (A$377m) is an interesting comparison to where PIQ is valued...

Where Renalytix may have an advantage is it’s relationship with the Icahn School of Medicine. Not just a collaboration, but a financial investment with a GBP14m investment in July 2019. Looks like they’re sitting on 9m cash at Dec-19. Certainty helpful for marketing efforts...

Deal #2: PIPE, $17.58M, Completed; 23-Jul-2019

Deal Types

PIPE

Deal Amount

$17.58M

Deal Status

Completed

Deal Date

23-Jul-2019

% Acquired

10.40%

Financing Status

Corporation

Financing Source

Corporate

Raised to Date

$40.93M **

Total Invested Equity

$17.58M

Total Invested Capital

$17.58M

Post Valuation

$169.04M E

CEO/Lead MGT

• James McCullough

  
  

  
  

Site

Cardiff, United Kingdom

Business Status

Generating Revenue

Deal Synopsis

The company (LON:RENX) received GBP 14 million of development capital from Icahn School of Medicine at Mount Sinai and other investors on July 23, 2019 through a private placement. The net proceeds of the Placing will be used towards the regulatory and clinical development to the company's lead AI-enabled kidney diagnostic product and towards working capital purposes to support the company's growth.

• ‡Not necessarily a summation of individual debt figures
• **Does not include grant funding
• EEstimated